Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of July 2019, with a specific reporting date of July 10, 2019. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) under the UK Market Abuse Regulation.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the transaction price for ordinary shares.
- Share Price: GBP 16.3622 per Ordinary Share.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
Material Changes
The filing does not report material changes to the company's business operations, financial condition, or strategic direction. It strictly documents routine acquisitions of shares by senior executives and their associates under the Company's Share Reward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transactions were executed on July 9, 2019, on the London Stock Exchange (XLON).
Important Facts for Investors
- Transaction Type: All reported transactions were acquisitions of Ordinary Shares under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Participants: Transactions were made by seven individuals, including CEO Emma Walmsley, President of Global Vaccines R.G. Connor, and Company Secretary Victoria Whyte.
- Volume: Individual transaction volumes were minimal, ranging from 14 to 16 shares per person.
- Valuation: The total value of shares acquired per individual was approximately GBP 230 to GBP 260.
- Limitation: This document is not a financial results report; investors should refer to Form 20-F or quarterly earnings releases for financial performance data.